Key facts
- Pregnolia’s last known valuation is $18.2M (Nov 2023).
- It has raised $14.7M; the latest was Later Stage VC ($4.4M) in Mar 2026.
- Notable investors include European Innovation Council, Venture Kick, Redstone VC, Verve Ventures, Zürcher Kantonalbank — 15 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for Pregnolia
- ·The full record, as it builds
Funding rounds
No funding rounds for Pregnolia are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Pregnolia
Developer of a pregnancy diagnostic tool designed to detect the early changes in the cervix. The company's technology helps measure the stiffness of the cervix for accurate characterization of cervical status to mitigate the risk of the premature birth of babies and also helps with early risk detection that permits gynecologists to make key decisions about preterm birth management, enabling doctors and midwives to provide improved pregnancy care and address both the health and economic challenges of preterm birth worldwide.
- Sector
- Healthcare
- HQ
- Schlieren, Switzerland
- Founded
- 2015
- Employees
- 8
- Website
- pregnolia.com/
- Ownership
- Privately Held (backing)
Pregnolia doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Pregnolia shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Pregnolia in its N-PORT filings yet. We sweep new filings monthly.